(19)
(11) EP 3 873 916 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
26.03.2025 Bulletin 2025/13

(45) Mention of the grant of the patent:
19.02.2025 Bulletin 2025/08

(21) Application number: 19877652.8

(22) Date of filing: 25.10.2019
(51) International Patent Classification (IPC): 
C07K 5/078(2006.01)
A61P 9/00(2006.01)
C07K 5/06(2006.01)
 A61P 7/02(2006.01)
C07K 5/04(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 5/06043; A61P 9/00; A61P 7/02
(86) International application number:
PCT/US2019/057985
(87) International publication number:
WO 2020/092139 (07.05.2020 Gazette 2020/19)

(54)

NOVEL DIPEPTIDE COMPOUNDS AND USES THEREOF

NEUARTIGE DIPEPTIDVERBINDUNGEN UND IHRE ANWENDUNGEN

NOUVEAUX COMPOSÉS DIPEPTIDIQUES ET LEURS UTILISATIONS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 29.10.2018 US 201862751984 P

(43) Date of publication of application:
08.09.2021 Bulletin 2021/36

(73) Proprietor: Shanghai Synergy Pharmaceutical Sciences, Ltd.
Shanghai 201203 (CN)

(72) Inventors:
  • LI, Min
    Ringoes, NJ 08551 (US)
  • HUANG, Yu
    Shanghai (CN)

(74) Representative: Maiwald GmbH 
Elisenhof Elisenstraße 3
80335 München
80335 München (DE)


(56) References cited: : 
EP-A1- 1 050 534
US-A1- 2005 085 517
US-B2- 6 774 110
 EP-A1- 2 639 230
US-B1- 6 288 077
US-B2- 6 774 110
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).